Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Juvenile Rheumatoid Arthritis
Etanercept a "Dramatic Advancement" in Treatment, Say Researchers
March 31st, 2000
A study conducted by researchers at Children's Hospital Medical Center of Cincinnati, Ohio, shows that nearly 75% of children with severe, long-standing juvenile rheumatoid arthritis (JRA) respond, often dramatically, to Enbrel (etanercept), a new drug. The study was published in the New England Journal of Medicine. "Enbrel represents the most dramatic advancement in treating JRA in recent years and is an improvement over current therapies in terms of both safety and effectiveness," said Daniel J. Lovell, MD, MPH, a pediatric rheumatologist at Cincinnati Children's and principal investigator of the national study. "Some patients who had...
Source: Drug Week (2000-03-31)
|
